10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
Regenxbio Inc. (RGNX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 4,368,804 | $36,610,578 | 2.42% | |
| 2. | Integral Health Asset Management Bhagwan Jay Rao | 1,500,000 | $12,570,000 | +25% | 0.6% |
| 3. | AQR Capital Management Cliff Asness | 1,051,712 | $8,813,347 | -23% | 0% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 554,892 | $4,649,995 | +1047% | 0% |
| 5. | Pale Fire Capital Dusan Senkypl, David Holy, And Jan Barta | 493,726 | $4,137,424 | -2% | 0.36% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 49,000 | $1,078,000.00 | 49,000 | 2015-09-22 | Filing | |
| $22.00 | 38,500 | $847,000.00 | 38,500 | 2015-09-22 | Filing | |
| $22.00 | 87,500 | $1,925,000.00 | 1,256,542 | 2015-09-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.02 | 15,309 | $168,705.18 | 232,617 | 2026-05-11 | Filing | |
| $10.35 | 5,124 | $53,033.40 | 247,926 | 2026-03-10 | Filing | |
| $12.62 | 20,811 | $262,634.82 | 216,162 | 2025-10-09 | Filing | |
| $10.03 | 7,624 | $76,468.72 | 236,973 | 2025-09-29 | Filing | |
| $10.02 | 7,734 | $77,494.68 | 244,597 | 2025-09-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,782,808 | $48,459,930 | 0% | |
| 2. | 3,483,800 | $27,069,126 | 0% | |
| 3. | 2,731,485 | $22,889,844 | 0% | |
| 4. | 2,066,157 | $17,314,400 | 0% | |
| 5. | 2,007,146 | $16,819,883 | 0% |
News See All
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2026 Earnings Call Transcript
Operator: Welcome, everyone, to the REGENXBIO RGX-2026 Top line Pivotal Data Webcast. At this time, I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of REGENXBIO.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to REGENXBIO Inc.'s fourth quarter and year-end 2025 earnings conference call. At this time, all participants are in a listen-only mode.
REGENXBIO Inc. (RGNX): A Bull Case Theory
We came across a bullish thesis on REGENXBIO Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on RGNX.
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2025 Earnings Call Transcript
Operator: Welcome, everyone, to the Third Quarter 2025 REGENXBIO Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
REGENXBIO Publishes Preclinical Data Highlighting RGX-202's Potential for Duchenne Muscular Dystrophy
REGENXBIO Inc. (NASDAQ:RGNX) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
REGENXBIO Inc. (RGNX): A Bull Case Theory
This stock is one of several featured in our latest research.
10 Promising SmallCap Stocks Under $1 Billion Market Cap
SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those willing to dig deeper.
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript
Operator: Welcome, everyone to the First Quarter 2025 REGENXBIO Earnings Conference Call. At this time, all participants are in a listen-only mode.
Hedge Fund Resource Center